{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:46:17Z","timestamp":1781880377919,"version":"3.54.5"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"Importance<\/jats:title>Previous studies have reported an association between hypoglycemia and cardiovascular (CV) events in people with type 2 diabetes (T2D), but it is unclear if this association is causal or identifies a high-risk patient phenotype.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the associations between hypoglycemia and CV outcomes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This secondary analysis was a post hoc assessment of the multinational, double-blind CARMELINA (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin; 2013-2016) and CAROLINA (Cardiovascular Outcome Trial of Linagliptin vs Glimepiride in Type 2 Diabetes; 2010-2018) randomized clinical trials of the antihyperglycemic drug, linagliptin, a dipeptidyl peptidase 4 inhibitor. Participants were adults with T2D at high CV risk with or without high kidney risk. By design, participants in the CARMELINA trial had longer duration of T2D and had a higher CV risk than participants in the CAROLINA trial. Data analyses were conducted between June 2021 and June 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Linagliptin or placebo in the CARMELINA trial, and linagliptin or glimepiride in the CAROLINA trial.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome for both trials was CV death, myocardial infarction (MI), or stroke (3-point major adverse CV events [3P-MACE]). For the present analyses, hospitalization for heart failure (HF) was added. Hypoglycemia was defined as plasma glucose less than 54 mg\/dL or severe hypoglycemia (episodes requiring the assistance of another person). Associations between the first hypoglycemic episode and subsequent CV events and between nonfatal CV events (MI, stroke, hospitalization for HF) and subsequent hypoglycemic episodes were assessed using multivariable Cox proportional hazards regression models. Sensitivity analyses explored the risk of CV events within 60 days after each hypoglycemic episode.<\/jats:p><\/jats:sec>Results<\/jats:title>In the CARMELINA trial (6979 patients; 4390 males [62.9%]; mean [SD] age, 65.9 [9.1] years), there was an association between hypoglycemia and subsequent 3P-MACE plus hospitalization for HF (hazard ratio [HR], 1.23; 95% CI, 1.04-1.46) as well as between nonfatal CV events and subsequent hypoglycemia (HR, 1.39; 95% CI, 1.06-1.83). In the CAROLINA trial (6033 patients; 3619 males (60.0%); mean [SD] age, 64.0 [9.5] years), there was no association between hypoglycemia and subsequent 3P-MACE plus hospitalization for HF (HR, 1.00; 95% CI, 0.76-1.32) and between nonfatal CV events and subsequent hypoglycemia (HR, 1.44; 95% CI, 0.96-2.16). In analyses of CV events occurring within 60 days after hypoglycemia, there was either no association or too few events to analyze.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study found bidirectional associations between hypoglycemia and CV outcomes in the CARMELINA trial but no associations in either direction in the CAROLINA trial, challenging the notion that hypoglycemia causes adverse CV events. The findings from the CARMELINA trial suggest that both hypoglycemia and CV events more likely identify patients at high risk for both.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01897532<\/jats:ext-link> (CARMELINA) and NCT01243424<\/jats:ext-link> (CAROLINA)<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.4602","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T16:02:29Z","timestamp":1704297749000},"page":"134","source":"Crossref","is-referenced-by-count":15,"title":["Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin"],"prefix":"10.1001","volume":"9","author":[{"given":"Nikolaus","family":"Marx","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Kolkailah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[{"name":"Therapeutic Area Cardiometabolism, Boehringer Ingelheim KS, Asker, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke Health, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, The University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Espeland","sequence":"additional","affiliation":[{"name":"Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schnaidt","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Ri\u00df, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Sydney, Newtown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Gollop","sequence":"additional","affiliation":[{"name":"Therapeutic Area Cardiometabolism, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas"},{"name":"Parkland Health, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hoi230065r1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management.","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"hoi230065r2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.2337\/diacare.26.5.1485","article-title":"Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.","volume":"26","author":"Desouza","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"hoi230065r3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.2337\/db08-1153","article-title":"Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control.","volume":"58","author":"Adler","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"hoi230065r4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2337\/dc09-2082","article-title":"Hypoglycemia, diabetes, and cardiovascular events.","volume":"33","author":"Desouza","year":"2010","journal-title":"Diabetes Care"},{"issue":"suppl 2","key":"hoi230065r5","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.2337\/dc11-s220","article-title":"Hypoglycemia and cardiovascular risks.","volume":"34","author":"Frier","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"hoi230065r6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.amjmed.2011.08.008","article-title":"Death during intensive glycemic therapy of diabetes: mechanisms and implications.","volume":"124","author":"Cryer","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"hoi230065r7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2337\/dc13-0701","article-title":"Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.","volume":"37","author":"Tsujimoto","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"hoi230065r8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/dc17-1778","article-title":"Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype.","volume":"41","author":"Standl","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"hoi230065r9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00125-017-4422-0","article-title":"DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.","volume":"61","author":"Pieber","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"hoi230065r10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial.","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"hoi230065r11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial.","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"hoi230065r12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12933-018-0682-3","article-title":"Rationale, design, and baseline characteristics of the Cardiovascular Safety and Renal Microvascular Outcome Study with Linagliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.","volume":"17","author":"Rosenstock","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"hoi230065r13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","article-title":"Design and baseline characteristics of the Cardiovascular Outcome Trial of Linagliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA).","volume":"12","author":"Marx","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"1","key":"hoi230065r14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-016-4146-6","article-title":"Glucose concentrations of less than 3.0 mmol\/l (54 mg\/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"60","author":"International Hypoglycaemia Study Group","year":"2017","journal-title":"Diabetologia"},{"issue":"5","key":"hoi230065r15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"hoi230065r17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proc R Soc Med"},{"issue":"15","key":"hoi230065r18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death.","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"hoi230065r19","doi-asserted-by":"publisher","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"issue":"24","key":"hoi230065r20","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi230065r21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes.","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi230065r22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2337\/dc19-1079","article-title":"Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL.","volume":"43","author":"Standl","year":"2020","journal-title":"Diabetes Care"},{"key":"hoi230065r16","volume-title":"Modelling Survival Data in Medical Research","author":"Collett","year":"2014","edition":"3rd ed"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2813068\/jamacardiology_marx_2024_oi_230065_1706752503.05619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:02:16Z","timestamp":1707926536000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2813068"}},"subtitle":["A Secondary Analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.4602","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}